Smith Micro Software (NASDAQ:SMSI – Get Free Report) and Coeptis Therapeutics (NASDAQ:ZSQR – Get Free Report) are both small-cap technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.
Risk and Volatility
Smith Micro Software has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.29, meaning that its stock price is 129% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations and price targets for Smith Micro Software and Coeptis Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Smith Micro Software | 1 | 0 | 2 | 0 | 2.33 |
| Coeptis Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
Smith Micro Software presently has a consensus target price of $12.50, suggesting a potential upside of 427.43%. Given Smith Micro Software’s stronger consensus rating and higher probable upside, equities analysts clearly believe Smith Micro Software is more favorable than Coeptis Therapeutics.
Earnings and Valuation
This table compares Smith Micro Software and Coeptis Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Smith Micro Software | $16.88 million | 0.78 | -$29.33 million | ($3.52) | -0.67 |
| Coeptis Therapeutics | $1.36 million | 157.05 | -$11.92 million | ($1.63) | -2.47 |
Coeptis Therapeutics has lower revenue, but higher earnings than Smith Micro Software. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Smith Micro Software, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Smith Micro Software and Coeptis Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Smith Micro Software | -92.60% | -44.59% | -31.78% |
| Coeptis Therapeutics | -773.72% | -49.45% | -46.88% |
Institutional and Insider Ownership
20.8% of Smith Micro Software shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 34.7% of Smith Micro Software shares are held by insiders. Comparatively, 24.2% of Coeptis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Smith Micro Software beats Coeptis Therapeutics on 11 of the 14 factors compared between the two stocks.
About Smith Micro Software
Smith Micro Software, Inc. engages in the development and sale of software to enhance the mobile experience to wireless and cable service providers in the Americas, Europe, the Middle East, and Africa. The company offers SafePath Family, SafePath IoT, SafePath Home, and SafePath Premium product suite, which provides tools to protect digital lifestyles and manage connected devices inside and outside the home; and CommSuite, a messaging platform that helps mobile service provides deliver a next-generation voicemail experience to mobile subscribers, as well as enables multi-language voice-to-text (VTT) transcription messaging. It also offers ViewSpot, a retail display management platform that provides on-screen and interactive demos to wireless carriers and other smartphone retailers; and technical support and customer services. Smith Micro Software, Inc. was founded in 1982 and is headquartered in Pittsburgh, Pennsylvania.
About Coeptis Therapeutics
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Receive News & Ratings for Smith Micro Software Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith Micro Software and related companies with MarketBeat.com's FREE daily email newsletter.
